TY - JOUR
TI - Covid-19 and Growth Hormone/Insulin-Like Growth Factor 1: Study in
Critically and Non-Critically Ill Patients
AU - Ilias, Ioannis
AU - Diamantopoulos, Aristidis
AU - Botoula, Efthymia and
AU - Athanasiou, Nikolaos
AU - Zacharis, Alexandros
AU - Tsipilis, Stamatios
AU - and Jahaj, Edison
AU - Vassiliou, Alice G.
AU - Vassiliadi, Dimitra A. and
AU - Kotanidou, Anastasia
AU - Tsagarakis, Stylianos
AU - Dimopoulou, Ioanna
JO - FRONTIERS IN ENDOCRINOLOGY
PY - 2021
VL - 12
TODO - null
SP - null
PB - Frontiers Media SA
SN - null
TODO - 10.3389/fendo.2021.644055
TODO - growth hormone; insulin-like growth factor 1; pandemics; severe acute
respiratory syndrome coronavirus 2; humans; hospitalization
TODO - Objective We aimed to measure insulin-like growth factor 1 (IGF1) and
growth hormone (GH) in critically and non-critically ill patients with
Covid-19 and assess them vis-a-vis clinical and laboratory parameters
and prognostic tools. Subjects and Methods We included patients who were
admitted to the wards or the ICU of the largest Covid-19 referral
hospital in Greece; patients with non-Covid-19 pneumonia served as
controls. Apart from the routine laboratory work-up for Covid-19 we
measured GH and IGF1 (and calculated normalized IGF-1 values as standard
deviation scores; SDS), after blood sampling upon admission to the wards
or the ICU. Results We studied 209 critically and non-critically ill
patients with Covid-19 and 39 control patients. Patients with Covid-19
who were ICU non-survivors were older and presented with a worse
hematological/biochemical profile (including white blood cell count,
troponin, glucose, aminotransferases and lactate dehydrogenase) compared
to ICU survivors or Covid-19 survivors in the wards. Overall, IGF-1 SDS
was higher in Covid-19 survivors compared to non-survivors (-0.96 +/-
1.89 vs -2.05 +/- 2.48, respectively, p=0.030). No significant
differences were noted in GH between the groups. Nevertheless, in
critically ill patients with Covid-19, the prognostic value of IGF-1
(raw data), IGF-1 (SDS) and GH for survival/non-survival was on a par
with that of APACHE II and SOFA (with a marginal difference between GH
and SOFA). Conclusion In conclusion, our findings suggest that there
might be an association between low IGF1 (and possibly GH) and poor
outcome in patients with Covid-19.
ER -